Allogene Therapeutics Inc

NASDAQ:ALLO   3:59:55 PM EDT
15.65
-0.17 (-1.08%)
Products

Allogene Reports FDA Clinical Hold Of AlloCAR T Trials Based On Single Patient Case In Alpha2 Trial

Published: 10/07/2021 20:58 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Reports FDA Clinical Hold of Allocar T Trials Based on a Single Patient Case in Alpha2 Trial.
Allogene Therapeutics - Believes Data From Alpha Trials Demonstrates a Favorable Clinical Profile of Allo-501a.
Allogene Therapeutics - FDA Continues to Review End of Phase 1 Materials for a Phase 2 Pivotal Trial of Allo-501a.
Allogene - Testing in a Patient With Low Blood Counts Showed Chromosomal Abnormality in Allo-501a Car T Cells of Unclear Clinical Significance.
Allogene Therapeutics Inc - Investigation is Underway to Further Characterize Observed Abnormality.